相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Parkinson disease
R. Balestrino et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Diagnosis and Treatment of Parkinson Disease A Review
Melissa J. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Design, synthesis, anticancer, antibacterial, and antifungal evaluation of 4-aminoquinoline-1,3,5-triazine derivatives
Hans Raj Bhat et al.
JOURNAL OF HETEROCYCLIC CHEMISTRY (2020)
Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A2A receptor (A2AR) antagonist for benefit in Parkinson's disease
Anup Masih et al.
NEUROSCIENCE LETTERS (2020)
Computational Multitarget Drug Design
Weilin Zhang et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)
Cognitive decline in Parkinson disease
Dag Aarsland et al.
NATURE REVIEWS NEUROLOGY (2017)
Non-motor features of Parkinson disease
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket
Bingfa Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase
Jitendra Kumar Srivastava et al.
SCIENTIFIC REPORTS (2017)
An update on the diagnosis and treatment of Parkinson disease
Philippe Rizek et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2016)
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Wolfgang Oertel et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Ageing, neurodegeneration and brain rejuvenation
Tony Wyss-Coray
NATURE (2016)
Synthesis, characterization and antimalarial activity of hybrid 4-aminoquinoline-1,3,5-triazine derivatives
Hans Raj Bhat et al.
ARABIAN JOURNAL OF CHEMISTRY (2016)
The application of in silico drug-likeness predictions in pharmaceutical research
Sheng Tian et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Synthesis, antimalarial activity and molecular docking of hybrid 4-aminoquinoline-1,3,5-triazine derivatives
Hans Raj Bhat et al.
EXPERIMENTAL PARASITOLOGY (2015)
Cell-based therapies for Parkinson disease-past insights and future potential
Roger A. Barker et al.
NATURE REVIEWS NEUROLOGY (2015)
Structure-guided discovery of 1,3,5-triazine-pyrazole conjugates as antibacterial and antibiofilm agent against pathogens causing human diseases with favorable metabolic fate
Babita Singh et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Pharmacological Treatment of Parkinson Disease A Review
Barbara S. Connolly et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
Amaal AlDakheel et al.
NEUROTHERAPEUTICS (2014)
Parkinson disease: from pathology to molecular disease mechanisms
David T. Dexter et al.
FREE RADICAL BIOLOGY AND MEDICINE (2013)
Antimalarial activity and docking studies of novel bi-functional hybrids derived from 4-aminoquinoline and 1,3,5-triazine against wild and mutant malaria parasites as pf-DHFR inhibitor
Hans Raj Bhat et al.
RSC ADVANCES (2013)
Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors
Xuwang Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Design, Synthesis, Antibacterial Activity, and Molecular Docking Studies of Novel Hybrid 1,3-Thiazine-1,3,5-Triazine Derivatives as Potential Bacterial Translation Inhibitor
Udaya P. Singh et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
Design, Facile Synthesis, and Antibacterial Activity of Hybrid 1,3,4-thiadiazole-1,3,5-triazine Derivatives Tethered via -S- Bridge
Vaibhav Dubey et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
Antimalarial evaluation and docking studies of hybrid phenylthiazolyl-1,3,5-triazine derivatives: A novel and potential antifolate lead for Pf-DHFR-TS inhibition
Prashant Gahtori et al.
EXPERIMENTAL PARASITOLOGY (2012)
Discovery of potent, novel antibacterial hybrid conjugates from 4-aminoquinoline and 1,3,5-triazine: design, synthesis and antibacterial evaluation
Hans Raj Bhat et al.
RSC ADVANCES (2012)
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
A. F. Ramlackhansingh et al.
NEUROLOGY (2011)
In vitro antimycobacterial activity of novel N'-(4-(substituted phenyl amino)-6-(pyridin-2-ylamino)-1,3,5-triazin-2-yl)isonicotinohydrazide
Jignesh Priyakant Raval et al.
MEDICINAL CHEMISTRY RESEARCH (2011)
Synthesis and antibacterial evaluation of series of novel tri-substituted-s-triazine derivatives
Udaya Pratap Singh et al.
MEDICINAL CHEMISTRY RESEARCH (2011)
Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine
Andrew S. Dore et al.
STRUCTURE (2011)
Novel 1,3,5-triphenyl-2-pyrazolines as anti-infective agents
P. M. Sivakumar et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Synthesis and Studies of New 2-(Coumarin-4-yloxy)-4,6-(substituted)-s-Triazine Derivatives as Potential Anti-HIV Agents
Dharmesh H. Mahajan et al.
ARCHIV DER PHARMAZIE (2009)
Computer-aided drug discovery and development (CADDD):: In silico-chemico-biological approach
I. M. Kapetanovic
CHEMICO-BIOLOGICAL INTERACTIONS (2008)
Adenosine A2A receptors in Parkinson's disease treatment
Marek Cieslak et al.
PURINERGIC SIGNALLING (2008)
The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist
Veli-Pekka Jaakola et al.
SCIENCE (2008)
Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function
Kjell Fuxe et al.
PHYSIOLOGY & BEHAVIOR (2007)
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
E. R. Dorsey et al.
NEUROLOGY (2007)
Targeting adenosine A2A receptors in Parkinson's disease
Michael A. Schwarzschild et al.
TRENDS IN NEUROSCIENCES (2006)
Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease
R Cools
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2006)
Adenosine A2A receptor antagonist treatment of Parkinson's disease
W Bara-Jimenez et al.
NEUROLOGY (2003)
Nonleadlikeness and leadlikeness in biochemical screening
GM Rishton
DRUG DISCOVERY TODAY (2003)
Neuroprotection by adenosine A(2A) receptor blockade in experimental models of Parkinson's disease
K Ikeda et al.
JOURNAL OF NEUROCHEMISTRY (2002)
[3H]ZM241385 -: an antagonist radioligand for adenosine A2A receptors in rat brain
SPH Alexander et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties
P Ertl et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
分享论文
